Update on hypertension and Alzheimer's disease

REFERENCES

• Dannenberg A, Garrison R, Kannel WB. Incidence of hyperten-sion in the Framingham study. Am Publ Health 1988; 78: 676–679
   PubMed Web of Science ®Google Scholar
• Kannel WB. Risk stratification in hypertension: New insights from the Framingham Study. Am Hypertens 2000; 13: 3S-10S
   Google Scholar
• Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia Lancet 1996; 347: 1141-1145
   Google Scholar
• Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49–55
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala E-L, Laakso M, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. Brit Med J2001; 322: 1447-1451
   Google Scholar
• Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen project: A 6- year follow-up study. Arch Neurol 2003; 60: 223–228
   PubMed Web of Science ®Google Scholar
• Ruitenberg A. Vascular factors in dementia. Observations in the Rotterdam Study, Rotterdam: Erasmus University, 2000
   Google Scholar
• Wu C, Zhou D, Wen C, et al. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci 2003; 72: 1125–1133
   PubMed Web of Science ®Google Scholar
• Whitmer R, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-281
   Google Scholar
• Luchsinger J, Reitz C, Honig L, et al. Aggregation of vascular risk factors and risk of incident Alzheimer's disease. Neurology 2005; 65: 545-551
   Google Scholar
• Posner HB, Tang MX, Luchsinger J, et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58: 1175–1181
   PubMed Web of Science ®Google Scholar
• Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995; 45: 1161–1168.
   PubMed Web of Science ®Google Scholar
• Morris MC, Scherr PA, Hebert LE, et al. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640–1646
   PubMedGoogle Scholar
• Shah R, Wilson R, Bienias J, et al. Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons. Neuroepidemiology 2006; 26: 30–36
   PubMed Web of Science ®Google Scholar
• Yamada M, Kasagi F, Sasaki H, et al. Association between dementia and midlife risk factors: The Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003; 51: 410–414
   PubMed Web of Science ®Google Scholar
• Bellew K, Pigeon J, Stang P, et al. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alz Dis Assoc Dis 2004; 18: 208–213
   PubMed Web of Science ®Google Scholar
• Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499
   PubMed Web of Science ®Google Scholar
• Qiu C, Winblad B, Viitanen M, et al. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke 2003; 34: 594–599
   PubMed Web of Science ®Google Scholar
• Freitag M, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia — The Honolulu—Asia Aging Study. Stroke 2006; 37: 33–37
   PubMed Web of Science ®Google Scholar
• Guo Z, Viitanen M, Fratiglioni L, et al. Low blood pressure and dementia in elderly people: The Kungsholmen project. Brit Med] 1996; 312: 805–808
   PubMed Web of Science ®Google Scholar
• Skoog I, Andreasson LA, Landahl S, et al. A population-based study on blood pressure and brain atrophy in 85-year-olds. Hypertension 1998; 32: 404–409
   PubMed Web of Science ®Google Scholar
• Hogan D, Ebly E, Rockwood K. Weight, blood pressure, osmolarity, and glucose levels across various stages of Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 1997; 8: 147–151
   PubMed Web of Science ®Google Scholar
• Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: Results from the Rotterdam Study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12: 33–39
   PubMed Web of Science ®Google Scholar
• Guo Z, Viitanen M, Winblad B, et al. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J Am Geriatr Soc 1999; 47: 723–726
   PubMed Web of Science ®Google Scholar
• Qiu C, von Strauss E, Winblad B, et al. Decline in blood pressure over time and risk of dementia — A longitudinal study from the Kungsholmen project. Stroke 2004; 35: 1810–1815
   PubMed Web of Science ®Google Scholar
• Petitti D, Crooks V, Buckwalter J, et al. Blood pressure-levels before dementia. Arch Neurol 2005; 62: 112–116
   PubMedGoogle Scholar
• Burke W, Coronado P, Schmitt C, et al. Blood pressure regulation in Alzheimer's disease. J Autonomic Nervous System 1994; 48: 65–71
   PubMedGoogle Scholar
• Passant U. Posture and brain function in dementia. A study with special reference to orthostatic hypotension. Thesis, Lund: University of Lund, 1996
   Google Scholar
• Hanon O, Latour F, Seux M, et al. Evolution of blood pressure in patients with Alzheimer's disease: A one year survey of a French cohort (REAL. FR). J Nutrition Health Aging 2005; 9: 106–111
   PubMed Web of Science ®Google Scholar
• Lantos P, Cairns N. The neuropathology of Alzheimer's disease. In: Burns A, Levy R, eds. Dementia, London: Chapman and Hall, 1994: pp. 185–207
   Google Scholar
• Chalmer J, Arnolda L, I L-S, et al. Central nervous control of blood pressure. In: Swales J, ed. Textbook of Hypertension, Oxford: Blackwell Scientific Publications, 1994,404–426
   Google Scholar
• Reis D. The brain and hypertension. Arch Neurol 1988; 45: 180–183
   PubMedGoogle Scholar
• de la Torre J. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis AssocDisord 2000; 14 (Suppl. 1): S72—S81
   Google Scholar
• Petrovitch H, White LR, lzmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 57–62
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162–169
   PubMed Web of Science ®Google Scholar
• Korf E, White L, Scheltens P, et al. Midlife blood pressure and the risk of hippocampal atrophy: The Honolulu Asia aging study. Hypertension 2004; 44: 29–34
   PubMed Web of Science ®Google Scholar
• den Heijer T, Launer L, Prins N, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64: 263–267
   PubMed Web of Science ®Google Scholar
• Korf E, Scheltens P, Barkhof F, et al. Blood pressure, white matter lesions and medial temporal lobe atrophy: Closing the gap between vascular pathology and Alzheimer's disease? Dem Geriatr Cogn Dis 2005; 20: 331–337
   PubMed Web of Science ®Google Scholar
• Wiseman R, Saxby B, Burton E, et al. Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects. Neurology 2004; 63: 1892–1897
   PubMed Web of Science ®Google Scholar
• Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–996
   PubMedGoogle Scholar
• Khachaturian A, Zandi P, Lyketsos C, et al. Anti-hypertensive medication use and incident Alzheimer's disease. The Cache County study. Arch Neurol, 2006; 63: 686–692
   PubMed Web of Science ®Google Scholar
• Skoog I, Lernfelt B, Landahl S. High blood pressure and dementia. Lancet 1996; 348: 65–66
   Web of Science ®Google Scholar
• Najjar L, Catoe H, Sixta S, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol Bio Sci Med Sci 2005; 60: 67–73
   PubMed Web of Science ®Google Scholar
• Guo Z, Fratiglioni L, Viitanen M, et al. Apolipoprotein E Genotypes and the Incidence of Alzheimer's disease among persons aged 75 years and older: Variation by use of anti-hypertensive medication? Am Epidemiol 2001; 153: 225–231
   PubMed Web of Science ®Google Scholar
• Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000; 48: 1035–1041
   PubMed Web of Science ®Google Scholar
• Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22: 407–412
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program. JAMA 1991; 265: 3255–3264
   PubMed Web of Science ®Google Scholar
• Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994; 154: 2154–2160
   PubMed Web of Science ®Google Scholar
• Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BM] 1996; 312: 801–805
   PubMed Web of Science ®Google Scholar
• Peart S, Brennan P, Broughton P, et al. Medical Research Council trial of treatment of hypertension in older adults: Principal results. 8M] 1992; 304: 405–412
   PubMed Web of Science ®Google Scholar
• Forette F, Seux M-L, Staessen J, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hyperten- sion in Europe (syst-Eur) trial. Lancet 1998; 352: 1347–1351
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046–2052
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertension 2003; 21: 875–886
   PubMed Web of Science ®Google Scholar
• Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function on cognitive and cardiovascular outcomes: Study on double-blind trial. Am] Hypertens 2005; 18: 1052–1059
   PubMed Web of Science ®Google Scholar
• Tzourio C, Anderson C, Chapman N, et al. Effects of blood disease. Arch Intern Med 2003; 163: 1069–1075
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–1041
   Google Scholar
• Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Rockwood K, Gauthier S eds. Trial Designs and Outcomes in Dementia Therapeutic Research: Abingdon: Taylor & Francis 2006
   Google Scholar
• Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644–1650
   PubMed Web of Science ®Google Scholar
• Rozzini L, Chilovi B, Bellelli G, et al. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. Int J Geriatr Psychiatry 2005; 20: 547–551
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Skoog I, Lane R, et al. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int Clin Pract 2003; 57: 756–760
   PubMed Web of Science ®Google Scholar
• Connelly P, Prentice N, Fowler K. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 2005; 20: 623–628
   PubMed Web of Science ®Google Scholar
• Skoog I, Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res 2003; 25: 675–680
   PubMed Web of Science ®Google Scholar
• Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E e4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14–20
   PubMed Web of Science ®Google Scholar
• Sparks D. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann N Y Acad Sci 1997; 826: 128–146
   PubMed Web of Science ®Google Scholar
• Gustafson D, Rothenberg E, Blennow K, et al. An 18-year follow-up of overweight and risk of Alzheimer's disease. Arch Internal Med 2003; 163: 1524–1528
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurology 2005; 62; 1556–1560
   PubMed Web of Science ®Google Scholar
• Rosengren A, Skoog I, Gustafson D, et al. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch Intern Med 2005; 165: 321–326
   PubMed Web of Science ®Google Scholar
• Whitmer R, Gunderson E, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. Brit Med J 2005; 330: 1360
   PubMed Web of Science ®Google Scholar
• Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002; 1: 61–77
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937–1942
   PubMed Web of Science ®Google Scholar
• Leibson C, Rocca W, Hanson V, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997; 145: 301–308
   PubMed Web of Science ®Google Scholar
• Peila R, Rodriguez BL, Launer Li. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia aging study. Diabetes 2002; 51: 1256–1262
   Google Scholar
• Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in japanese-american elderly men: The honolulu-asia aging study. Arterioscler Thromb VascBiol 2000; 20: 2255–2260
   PubMed Web of Science ®Google Scholar
• Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 1997; 315: 1045–1049
   PubMed Web of Science ®Google Scholar
• Skoog I, Gustafson D. Vascular disorders and Alzheimer's disease. In: Bowler J, Hachinski V, eds. Vascular Cognitive Impairment. Preventable Dementia, Oxford New York: Oxford University Press, 2003: pp. 260–271
   Google Scholar
• de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 1999; 46: 827–833
   PubMed Web of Science ®Google Scholar
• de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002; 125: 765–772
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222
   PubMed Web of Science ®Google Scholar
• Liebetrau M, Steen B, Hamann G, et al. Silent and symptomatic infarcts on cranial computerized tomography in relation to dementia and mortality. A population-based study in 85-year-olds. Stroke 2004; 35: 1816–1820
   PubMed Web of Science ®Google Scholar
• Tatemichi TK, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994; 44: 1885–1891
   PubMed Web of Science ®Google Scholar
• Liebetrau M, Steen B, Skoog I. Stroke in 85-year-olds. Prevalence, incidence, risk factors and relation to mortality and dementia. Stroke 2003; 34: 2617–2622
   PubMed Web of Science ®Google Scholar
• Linden T, Skoog I, Fagerberg B, et al. Cognitive impairment and dementia 20 months after stroke. Neuroepidemiology 2004; 23: 45–52
   PubMed Web of Science ®Google Scholar
• Skoog I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Disord 1998; 9: 13–19
   PubMed Web of Science ®Google Scholar
• Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986; 19: 253–262
   PubMed Web of Science ®Google Scholar
• Ble A, Ranzini M, Zurlo A, et al. Leukoaraiosis is associated with functional impairment in older patients with Alzheimer's disease but not vascular dementia. J Nutrition Health Aging 2006; 10: 31–35
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Den Heijer T, Koudstaal Pi, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003; 34: 392–396
   PubMed Web of Science ®Google Scholar
• Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999; 47: 564–569
   PubMed Web of Science ®Google Scholar
• Nagy Z, Esiri M, Jobst K, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 165–170
   PubMed Web of Science ®Google Scholar
• Heyman A, Fillenbaum G, Welsh-Bohmer K, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer's disease. Neurology 1998; 51: 159–162
   PubMed Web of Science ®Google Scholar
• (CFAS) NGotMRCCFaASM. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet.2001; 357: 169-175
   Google Scholar
• Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br] Psychiatry 1999; 174: 45–50
   PubMed Web of Science ®Google Scholar
• Snowdon D, Greiner L, Mortimer J, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813–817
   PubMed Web of Science ®Google Scholar
• Riekse R, Leverenz J, McCormick W, et al. Effect of vascular lesions on cognition in Alzheimer's disease: A community-based study. J Am Ger Soc 2004; 52: 1442–1448
   PubMed Web of Science ®Google Scholar
• Jendroska K, Poewe W, Daniel S, et al. Ischemic stress induces deposition of amyloid b immunoreactivity in human brain. Acta Neuropathol 1995; 90: 461–466
   PubMed Web of Science ®Google Scholar
• de la Torre J. Critically attained threshold of cerebral hypoperfu-sion: Can it cause Alzheimer's disease? Ann N Y Acad Sci 2000; 903: 424–436
   PubMed Web of Science ®Google Scholar
• Kalback W, Esh C, Castano E, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 2004; 26: 525–539
   PubMed Web of Science ®Google Scholar
• Hanon O, Haulon S, Lenoir H, et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 2005; 36: 2193–2197
   PubMed Web of Science ®Google Scholar
• Girouard H, ladecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006; 100: 328–335
   PubMed Web of Science ®Google Scholar
• Hall E, Oostveen J, Dunn E, et al. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 1995; 135: 17–27
   PubMed Web of Science ®Google Scholar
• Bennett SA, Pappas BA, Stevens WD, et al. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 2000; 21: 207–214
   PubMed Web of Science ®Google Scholar
• Kalaria R, Bhatti S, Palatinsky E, et al. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport 1993; 4:211–214
   PubMed Web of Science ®Google Scholar
• Weidemann A, Pal iga K, Durrwang U, et al. Formation of stable complexes between two Alzheimer's disease gene products: Presenil in-2 and beta-amyloid precursor protein. Nat Med 1997; 3: 328–332
   PubMed Web of Science ®Google Scholar
• Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenil in-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387–390
   PubMed Web of Science ®Google Scholar
• Citron M, Eckman C, Diehl T, et al. Additive effects of P51 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis 1998; 5: 107–116
   PubMed Web of Science ®Google Scholar
• Sudoh S, Kawamura Y, Sato S, et al. Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites. J Neurochem 1998; 71: 1535–1543
   PubMed Web of Science ®Google Scholar
• Pennypacker K, Hernandez H, Benkovic S, et al. Induction of presenil ins in the rat brain after middle cerebral arterial occlusion. Brain Res Bull 1999; 48: 539–543
   PubMed Web of Science ®Google Scholar
• Tanimukai H, Imaizumi K, Kudo T, et al. Alzheimer-associated presenil in-1 gene is induced in gerbil hippocampus after transient ischemia. Brain Res Mol Brain Res 1998; 54: 212–218
   PubMedGoogle Scholar
• Guo X, Sjögren K, Waern M, et al. Midlife Lung Function and Incidence of Alzheimer's disease: A 29-year Ingitudinal study in women. Neurobiol Aging, to be published.
   Google Scholar
• Nakano D, Hayashi T, Tazawa N, et al. Chronic hypoxia accelerates the progression of atherosclerosis in apolipoprotein E-knockout mice. Hypertens Res 2005; 28: 837–845
   PubMed Web of Science ®Google Scholar
• Simanonok J. Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Med Hypoth 1996; 46: 155–161
   PubMed Web of Science ®Google Scholar
• Mooradian A. Effect of aging on the blood-brain barrier. Neurobiol Aging 1988; 9: 31–39
   PubMed Web of Science ®Google Scholar
• Johansson B. Cerebral vascular bed in hypertension and consequences for the brain. Hypertension 1984; 6 (Suppl. 3): 81-86
   Google Scholar
• Johansson B. Pathogenesis of vascular dementia: The possible role of hypertension. Dementia 1994; 5: 174–176
   PubMedGoogle Scholar
• Nag S. Cerebral changes in chronic hypertension: Combined permeability and immunohistochemical studies. Acta Neuropathol (Berlin) 1984; 62: 178–184
   PubMed Web of Science ®Google Scholar
• Shah GN, Mooradian AD. Age-related changes in the blood-brain barrier. Exp Gerontol 1997; 32: 501–519
   PubMed Web of Science ®Google Scholar
• Wisniewski H, Kozlowski P. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann NY Acad Sci 1982; 396:119–131
   PubMed Web of Science ®Google Scholar
• Licandro A, Ferla S, Tavolato B. Alzheimer&s disease and senile brains: An immunofluorescence study. Riv Pat Nerv Ment 1983; 104: 75–87
   PubMedGoogle Scholar
• Eikelenboom P, Stam F. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol (Berlin) 1982; 57: 239–242
   PubMed Web of Science ®Google Scholar
• Mann D, Davies J, Hawkes J, et al. Immunohistochemical staining of senile plaques. Neuropathol Appl Neurobiol 1982; 8: 55–61
   PubMed Web of Science ®Google Scholar
• Hampel H, Muller-Spahn F, Berger C, et al. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: A possible indicator for immunoacticvation. Dementia 1995; 6: 348–354
   PubMedGoogle Scholar
• Elovaara I, Icén A, Palo J, et al. CSF in Alzheimer's disease. Studies on blood-brain barrier function and intrathecal protein synthesis. J Neurol Sci 1985; 70: 73–80
   PubMed Web of Science ®Google Scholar
• Elovaara I, Seppälä I, Palo J, et al. Oligo-clonal immunoglobul in bands in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Acta Neurol Scand 1988; 77: 397–401
   PubMedGoogle Scholar
• Blennow K, Wallin A, Fredman P, et al. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990; 81: 349–351
   PubMedGoogle Scholar
• Skoog I, Wallin A, Fredman P, et al A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966–971
   PubMed Web of Science ®Google Scholar
• Glenner G. Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypoth 1979; 5: 1231–1236
   PubMed Web of Science ®Google Scholar
• Hardy J, Mann D, Wester P, et al. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 1986; 7: 489–502
   PubMed Web of Science ®Google Scholar
• Lethem R, Orrell M. Antioxidants and dementia. Lancet 1997; 349: 1189–1190
   PubMed Web of Science ®Google Scholar
• Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462
   PubMed Web of Science ®Google Scholar
• Hamet P, Richard L, Dam T-V, et al. Apoptosis in target organs of hypertension. Hypertension 1995; 26: 642–648
   PubMed Web of Science ®Google Scholar
• Wright J, Harding J. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav R 1994; 18: 21–53
   PubMed Web of Science ®Google Scholar
• Ekeberg O, Kjeldsen S, Eide I, et al. Childhood traumas and psychosocial characteristics of 50-year-old men with essential hypertension. J Psychosom Res 1990; 34: 643–649
   PubMed Web of Science ®Google Scholar
• Persson G, Skoog I. A prospective population study of psycho-social risk factors for late-onset dementia. Int J Geriatric Psychiatry 1996; 11: 15–22
   Web of Science ®Google Scholar
• Huxley R, Shiell A, Law C. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: A systematic review of the literature. J Hypertens 2000; 18: 815–831
   PubMed Web of Science ®Google Scholar
• Graves AB, Mortimer JA, Larson EB, et al. Head circumference as a measure of cognitive reserve association with severity of impairment in Alzheimer's disease. Brit] of Psychiatry 1996; 169: 86-92
   Google Scholar
• Arendash G, Su G, Crawford F, et al. Intravascular beta-amyloid infusion increases blood pressure: implications for a vasoactive role of beta-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 1999; 268: 17–20
   PubMed Web of Science ®Google Scholar
• Suo Z, Humphrey J, Kundtz A, et al. Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett 1998; 257: 77–80
   PubMed Web of Science ®Google Scholar
• Thomas T, Thomas G, McLendon C, et al. b-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168–171
   PubMed Web of Science ®Google Scholar
• Luscher T. Local relaxant and constricting factors in the vessel wall. In: Swales J, ed. Textbook of Hypertension, Oxford: Blackwell Scientific Publications, 1994: 144–159
   Google Scholar
• Umans J. Less nitric oxide, more pressure, or the converse? Lancet 1997; 349: 816
   PubMed Web of Science ®Google Scholar
• Skoog I. The interaction between vascular disorders and Alzheimers disease. In: lqbal K, Swaab D, Winblad B, et al., eds. Alzheimer's Disease and Related Disorders: Etiology, Pathogenesis and Therapeutics, Chichester: John Wiley & Sons Ltd, 1999: pp. 523-530
   Google Scholar
• Skoog I. Possibilities for secondary prevention of Alzheimers disease. In: Mayeux R, Christen Y, eds. The Epidemiology of Alzheimer's Disease: From Gene to Prevention, Berlin: Springer Verlag, 1999: 121–134
   Google Scholar